SMR 2024 | How can ctDNA assays improve clinical decisions in high-risk melanoma?
Meghan Mooradian, MD, Massachusetts General Hospital, Boston, MA, comments on the unique ability of circulating tumor DNA (ctDNA) assays to enhance real-time monitoring for biomarkers of tumor response or resistance. ctDNA assays can improve risk-stratification and clinical decision-making by assessing minimal residual disease and molecular surveillance for the likelihood of macroscopic recurrence in patients. Dr Mooradian is optimistic about the standardized use of ctDNA assays in future post-operative strategies such as the escalation or de-escalation of therapy for patients with high-risk melanoma. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
